Ranbaxy’s CEO has confidently asserted that the US Food and Drug Administration’s (FDA) court action will be dropped in the near future and fired another warning shot at the “negative elements” he believes were behind the controversy.
The first steps in tightening the safety controls on the
pharmaceutical ingredients imported to the US from China have been
taken following months of negotiations between the regulatory
bodies of the two countries.
Organon, Akzo Nobel's healthcare division, has conceded it will
have to close its Diosynth manufacturing plant in Scotland by the
end of the year since it cannot divest it, as the unit's lack of
competitiveness in the production...
Germany's Girindus is this year's recipient of the Product
Differentiation Award sponsored by consulting firm Frost &
Sullivan for its innovative developments in the commercial
production of oligonucleotides.
The restructuring activity that has features this year in the
European pharmachem industry continued yesterday with the news that
Germany's Merck KGaA had sold off BioMer, a joint venture focusing
on orthopaedic products.